Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019525 | 0.84 | GAA (0.50) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL19793353 | 0.84 | GAA (0.50) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL2257043 | 0.83 | HTR2C (0.42) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL469553 | 0.80 | GAA (0.46) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL2256657 | 0.80 | CYP2C9 (0.40) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL15131365 | 0.79 | L3MBTL1 (0.46) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL3366596 | 0.79 | GAA (0.47) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL30485468 | 0.79 | L3MBTL1 (0.47) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL17578004 | 0.79 | L3MBTL1 (0.47) | L3MBTL1GAATDP1CYP2C9CYP2C19 | |
| SCHEMBL16451179 | 0.79 | GAA (0.45) | L3MBTL1GAATDP1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | disclosed |
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| EP-2691413-B1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | L3MBTL1 2040/4885GAA 2904/4885TDP1 1409/4885 |
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | L3MBTL1 3984/4885GAA 835/4885TDP1 4364/4885 |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | L3MBTL1 794/4885GAA 990/4885TDP1 631/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | L3MBTL1 794/4885GAA 990/4885TDP1 631/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | L3MBTL1 794/4885GAA 990/4885TDP1 631/4885 |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | L3MBTL1 794/4885GAA 990/4885TDP1 631/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | L3MBTL1 794/4885GAA 990/4885TDP1 631/4885 |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | MAVS, HDGF, TTPA | L3MBTL1 2765/4885GAA 2152/4885TDP1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.